


What is claimed is:

1. A composition of matter comprising
 - a. ~~an~~ integrin/adhesion antagonist peptide; and
 - b. a vehicle.

- 5 2. A composition of the formula



and multimers thereof, wherein:

F^1 is an Fc domain;


X^1 and X^2 are each independently selected from $-(L^1)_c-P^1$, $-(L^1)_c-P^1-(L^2)_d-P^2$, $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$, and $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$

P^1 , P^2 , P^3 , and P^4 are each independently sequences of integrin/adhesion antagonist peptides;


L^1 , L^2 , L^3 , and L^4 are each independently linkers; and

15 a , b , c , d , e , and f are each independently 0 or 1, provided that at least one of a and b is 1.


3. The composition of matter of Claim 1 of the formulae



4. The composition of matter of Claim 3 of the formula



5. The composition of matter of Claim 3 of the formula



- 25 6. The composition of matter of Claim 2, wherein F^1 is an Fc domain.

7. The composition of matter of Claim 2 wherein F^1 is an IgG Fc domain.

8. The composition of matter of Claim 2 wherein F^1 is an IgG1 Fc domain.

A-688A

9. The composition of matter of Claim 2 wherein F¹ comprises the sequence of SEQ ID NO: 2.
10. The composition of matter of Claim 2 wherein X¹ and X² comprise one or more sequences selected from SEQ ID NOS: 7 to 21.
- 5 11. The composition of matter of Claim 2 wherein the composition of matter comprises one or more sequences selected from SEQ ID NOS: 22 to 94.
12. The composition of matter of Claim 2 wherein the composition of matter comprises one or more sequences selected from SEQ ID
- 10 NOS: 7 and 9 to 16.
- 13 13. The composition of matter of Claim 2 wherein the composition of matter comprises one or more sequences selected from Tables 3, 4, 5, and 6 (SEQ ID NOS: 22 to 94, 128 to 137).
14. A DNA encoding a composition of matter of any of Claims 6 to 13.
- 15 15. An expression vector comprising the DNA of Claim 14.
16. A host cell comprising the expression vector of Claim 15.
17. The cell of Claim 16, wherein the cell is an E. coli cell.
18. A process for preparing a pharmacologically active compound, which comprises
- 20 a) selecting at least one randomized integrin/adhesion antagonist peptide; and
- b) preparing a pharmacologic agent comprising at least one Fc domain covalently linked to at least one amino acid sequence of the selected peptide or peptides.
- 25 19. The process of Claim 18, wherein the peptide is selected in a process comprising one or more techniques selected from yeast-based screening, rational design, protein structural analysis, screening of a phage display library, an E. coli display library, a ribosomal library, or a chemical peptide library.

A-688A

20. The process of Claim 18, wherein the preparation of the pharmacologic agent is carried out by:
- a) preparing a gene construct comprising a nucleic acid sequence encoding the selected peptide and a nucleic acid sequence encoding an Fc domain; and
 - b) expressing the gene construct.
21. The process of Claim 18, wherein the gene construct is expressed in an E. coli cell.
22. The process of Claim 18 wherein the Fc domain is an IgG Fc domain.
23. The process of Claim 18, wherein the vehicle is an IgG1 Fc domain.
24. The process of Claim 18, wherein the vehicle comprises the sequence of SEQ ID NO: 2.
25. A composition of matter comprising an amino acid sequence selected from SEQ ID NOS: 132 to 137.

15

sub
all